Literature DB >> 24321396

Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation.

Arije Ghannam1, Jean-Luc Fauquert2, Caroline Thomas3, Claudia Kemper4, Christian Drouet5.   

Abstract

Human T helper type 1 (Th1) responses are essential in defense. Although T cell receptor (TCR) and co-stimulator engagement are indispensable for T cell activation, stimulation of additional receptor pathways are also necessary for effector induction. For example, engagement of the complement regulator CD46 by its ligand C3b generated upon TCR activation is required for IFN-γ production as CD46-deficient patients lack Th1 responses. Utilizing T cells from two C3-deficient patients we demonstrate here that normal Th1 responses also depend on signals mediated by the anaphylatoxin C3a receptor (C3aR). Importantly, and like in CD46-deficient patients, whilst Th1 induction are impaired in C3-deficient patients in vitro, their Th2 responses are unaffected. Furthermore, C3-deficient CD4(+) T cells present with reduced expression of CD25 and CD122, further substantiating the growing notion that complement fragments regulate interleukin-2 receptor (IL-2R) assembly and that disturbance of complement-guided IL-2R assembly contributes to aberrant Th1 effector responses. Lastly, sustained intrinsic production of complement fragments may participate in the Th1 contraction phase as both C3a and CD46 engagement regulate IL-10 co-expression in Th1 cells. These data suggest that C3aR and CD46 activation via intrinsic generation of their respective ligands is an integral part of human Th1 (but not Th2) immunity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C3 deficiency; C3a; Complement; T cell effector response

Mesh:

Substances:

Year:  2013        PMID: 24321396     DOI: 10.1016/j.molimm.2013.11.010

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  45 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

2.  A C3(H20) recycling pathway is a component of the intracellular complement system.

Authors:  Michelle Elvington; M Kathryn Liszewski; Paula Bertram; Hrishikesh S Kulkarni; John P Atkinson
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

Review 3.  Production of complement components by cells of the immune system.

Authors:  R Lubbers; M F van Essen; C van Kooten; L A Trouw
Journal:  Clin Exp Immunol       Date:  2017-03-24       Impact factor: 4.330

Review 4.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

5.  Radiotherapy: killing with complement.

Authors:  Jean F Regal; Kenneth J Dornfeld; Sherry D Fleming
Journal:  Ann Transl Med       Date:  2016-03

6.  Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion.

Authors:  Tingjun Chen; Vanda A Lennon; Yong U Liu; Dale B Bosco; Yujiao Li; Min-Hee Yi; Jia Zhu; Shihui Wei; Long-Jun Wu
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 7.  Effects of complement activation on allograft injury.

Authors:  Joong Hyuk Sheen; Peter S Heeger
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

Review 8.  Complement-Mediated Regulation of Metabolism and Basic Cellular Processes.

Authors:  Christoph Hess; Claudia Kemper
Journal:  Immunity       Date:  2016-08-16       Impact factor: 31.745

Review 9.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

Review 10.  Complement and Transplantation: From New Mechanisms to Potential Biomarkers and Novel Treatment Strategies.

Authors:  Julian K Horwitz; Nicholas H Chun; Peter S Heeger
Journal:  Clin Lab Med       Date:  2018-12-20       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.